Volume-09 Issue 03, March-2025 ISSN: 2456-9348
Impact Factor: 8.232

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

THE CHALLENGES FOR MANUFACTURERS OF THE INCREASED CLINICAL EVALUATION REQUIREMENTS UNDER THE EUROPEAN UNION MEDICAL DEVICE REGULATIONS

[1]Chrysoula I. Liakou, MD, PhD, Director. Clinical Evaluation Department. National Evaluation Center of Quality and Technology in Health, Athens, Greece.
liakou@ekapty.gr

[2]Marios Papadakis, MD, PhD. Department of Surgery II
University of Witten-Herdecke. Wuppertal, Germany.
marios_papadakis@yahoo.gr

[3] Markos Plytas, MSc. Academic Director. Epsilon College. Athens, Greece.
m.plytas@epsilonnet.gr

ABSTRACT
The European Union Medical Device Regulations EU MDR established new demanding clinical evaluation criteria that substantially affect medical equipment manufacturers. The EU MDR imposes rules that require manufacturers to provide advanced clinical proof and maintain continuous surveillance of their products under strict notification body oversight. Manufacturers encounter multiple obstacles due to the enhancements that were introduced to improve patient safety and device effectiveness. In addition, the shortage of approved notified bodies causes delays in market entry for new devices and existing products. Small and medium-sized enterprises (SMEs) face adverse effects from compliance costs, which leads them to eliminate products or stop selling in markets. Companies face challenges to innovation since they must dedicate substantial resources to fulfill transforming regulatory standards. The following study provides a deep examination of these regulatory challenges, including their industrial effects on the medical device sector, along with manufacturer-approved navigation strategies.

Keywords:
EU MDR, Medical Device Regulations, Clinical Evaluation, Notified Bodies, Regulatory Compliance, Clinical Evidence, Medical Device Manufacturers, Post-Market Surveillance, Approval Process, Regulatory Challenges.

INTRODUCTION

The medical device market in the European Union (EU) is one of the largest and most dynamic sectors within the healthcare industry. It encompasses a wide range of products, from simple instruments like bandages and thermometers to complex devices such as pacemakers, diagnostic imaging systems, and surgical robots. The EU market is highly regulated to ensure the safety, performance, and efficacy of these devices, with the Medical Device Regulation (MDR) and In Vitro Diagnostic Device Regulation (IVDR) providing the legal framework for their approval and market surveillance. These regulations, enforced since May 2021, replaced the previous Medical Device Directive (MDD) and the In Vitro Diagnostic Directive (IVDD), aiming to improve patient safety and address emerging technological advancements in the medical device sector).

The European medical device market is highly competitive, with both established multinational companies and small to medium-sized enterprises (SMEs) striving to introduce innovative products. According to the European Commission, the market value for medical devices in the EU is estimated to exceed €100 billion annually, with steady growth driven by an ageing population, technological advancements, and increased healthcare spending. Despite these growth prospects, companies face several challenges, including navigating the complex regulatory landscape, ensuring

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

product compliance with stringent requirements, and addressing market access delays due to the limited number of notified bodies. These challenges underscore the need for manufacturers to maintain robust post-market surveillance systems and to adapt to evolving regulatory standards to stay competitive in the EU market.

Manufacturers are required to provide robust clinical evidence to establish their products' safety and effectiveness. Notified bodies must conduct more comprehensive clinical investigations, alongside post-market surveillance and continuous monitoring. The clinical investigation requirements under the MDR exceed those of the Medical Device Directive, which was the previous status quo, especially for higher-risk devices, leading to extended approval timelines and increased financial burdens.

Manufacturers must also meet new post-market surveillance (PMS) and post-market clinical follow-up (PMCF) obligations, which require the ongoing collection and analysis of device performance data. This shift from single-time assessments to continuous monitoring increases operational costs and necessitates specialised expertise and infrastructure.

A key challenge for manufacturers is the variability in how notified bodies interpret the MDR, leading to inconsistent compliance expectations and delays in the approval process. The limited number of authorised notified bodies exacerbates these issues, resulting in prolonged market entry delays for new device developers.

The table below summarizes key differences between the previous MDD framework and the current MDR framework:

Table 1: Key Differences Between MDD and MDR Clinical Evaluation Requirements

Aspect	Medical Device Directive (MDD)	Medical Device Regulation (MDR)
Clinical Evidence Requirement	Relied on equivalence to existing devices with minimal new clinical data.	Requires comprehensive clinical investigations, particularly for high-risk devices.
Post-Market Surveillance (PMS)	Less stringent PMS requirements.	Mandates continuous data collection, including post-market clinical follow-up (PMCF).
Notified Body Oversight	Less frequent and less rigorous assessments.	Stricter oversight, more frequent audits, and higher scrutiny of clinical data.
Time-to-Market	Faster approval due to lower clinical evidence requirements.	Longer approval process due to increased clinical evaluation demands.
Impact on SMEs	Easier compliance for small and medium-sized enterprises.	Higher costs and complexity make compliance more challenging for SMEs.

The paper examines the industry's struggles, which it explains together with major regulatory obstacles, before suggesting methods to manage this changing environment successfully. Medical device manufacturers gain better control by identifying these challenges, which helps them adjust to EU regulatory changes and sustain competitiveness in this market segment.

METHODOLOGY

The research analyzes medical device manufacturer challenges through qualitative methods with a specific focus on the intensified EU MDR clinical evaluation needs. Regulatory documents, industry reports, and academic literature serve as main sources in this research to determine both significant areas of concern along with their effect on manufacturers.

The research data gathers information through these three sources:

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/



The purpose of this assessment integrates multiple database sources to offer an organized evaluation of the hurdles manufacturers need to overcome regarding MDR clinical evaluation compliance. The study finds that it presents information about the regulatory discrepancies alongside financial and operational challenges that manufacturers should utilize to work through this changing compliance context.

RESULTS

The research showed that medical device producers encounter important difficulties from enhanced clinical testing demands in the framework of EU MDR regulations. The strict EU regulations have created substantive operational, financial, and procedural barriers for businesses that aim to achieve regulatory compliance with these standards.

The MDR necessitates more extensive and higher-quality clinical data to substantiate the safety and efficacy of medical devices. In contrast to the previous Medical Device Directive (MDD), which permitted manufacturers to rely more heavily on equivalence data from similar devices, the MDR demands direct clinical evidence obtained through clinical investigations, particularly for higher-risk devices. This shift has resulted in increased costs, longer study durations, and heightened regulatory scrutiny. Small and medium-sized enterprises (SMEs) face particular challenges in bearing the financial burden of conducting new clinical trials.

Notified bodies maintain essential responsibility for checking how manufacturers fulfill their obligations under MDR requirements. Different notified bodies show inconsistent evaluation practices when implementing clinical evaluation protocols. Regulatory approval processes for manufacturers become uncertain because different notified bodies maintain varying levels of strictness in their evidence standard demands. Manufacturers must adapt to multiple sets of requirements when different notified bodies evaluate their products and this leads to multiple documentation submission rounds and revisions, thus extending approval timelines.

The MDR implementation resulted in a major reduction of available notified bodies that perform medical device assessments. The majority of MDD-operated notified bodies now face two difficulties: they lack MDR designation status or must handle an expanded workload. The duration of device certification processes causes manufacturing

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

companies to encounter extended delays for product release and market launch. Innovative medical devices suffer the most from the bottleneck because they need intensive clinical evaluation processes.

Compliance with the MDR's clinical evaluation requirements necessitates substantial financial investment. The process requires major financial investment for clinical studies, along with regulatory consultant fees and continual post-market surveillance functions. The increased regulatory requirements create significant problems for manufacturers, especially those companies that include startups and SMEs because they lack sufficient financial resources. Several European manufacturers chose market withdrawal for their products because of excessive compliance expenses.

The MDR medical device approval process now demands a significant extension of review times until manufacturers receive clearance. Under the former MDD framework, manufacturers could expedite their approval by depending on existing literature and equivalence data. Under the MDR, manufacturers must conduct fresh clinical studies while maintaining ongoing post-market surveillance, thus prolonging their time required for regulatory review. Manufacturers experience slower time-to-market performance because longer approval durations create problems for emergency global medical technology market competitiveness.

The MDR promotes enhanced post-market surveillance through PMS requirements and mandates PMCF standards. All manufacturers need to keep tracking the safety and performance of their medical devices following market launch to report all detected product hazards and unacceptable events. Compliance teams must be created, and long-term data collection systems must be implemented according to the requirements of the regulation. The reinforced patient safety initiatives create substantial long-term operational challenges for medical device manufacturers. The following data provides an overview of the analysis:

Table 2: Key Challenges and Their Impact on Medical Device Manufacturers

Challenge	Description	Impact on Manufacturers
Increased Clinical Evidence Requirements	MDR mandates higher-quality clinical data, including clinical investigations and post-market clinical follow-ups.	Higher costs for clinical trials and longer product development cycles.
Variability Among Notified Bodies	Different notified bodies interpret clinical evaluation requirements differently.	Uncertainty in compliance expectations and delays in approval.
Limited Availability of Notified Bodies	Fewer notified bodies designated under MDR, leading to backlog issues.	Prolonged approval times, delayed market entry.
Financial and Operational Burden	Compliance requires significant financial investment in clinical studies and regulatory consulting.	Increased costs and potential challenges for small manufacturers.
Extended Time-to-Market	Additional clinical evidence and stricter evaluations lengthen the regulatory review process.	Slower product launches, loss of competitive advantage.
Post-Market Surveillance Obligations	Enhanced requirements for ongoing data collection and reporting.	Continuous compliance burden, need for dedicated resources.

Data shows that the EU MDR acts as a patient safety tool, but manufacturers still encounter numerous implementation barriers. Organization-wide efforts need to develop plans together with regulatory body interactions and expenditures toward compliance management solutions to address current challenges.

DISCUSSION

The research outcomes demonstrate that manufacturers of medical devices encounter major difficulties because of stricter European Union Medical Device Regulations (EU MDR) clinical evaluation rules. The main purpose of the MDR is to improve patient safety and validate medical device effectiveness; however, its stringent system creates

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

complex barriers affecting manufacturing companies in multiple dimensions. This paper offers a thorough analysis of the challenges that businesses in the medical devices industry face alongside their industry impacts and solution strategies.

The extensive demand for MDR arises from its requirement for complete clinical evidence documentation. Manufacturers experienced a major change under MDR since direct clinical investigations became mandatory for various device categories, while the previous MDD allowed equivalent data from related devices for compliance.

Clinical trial expenses have risen due to the manufacturing requirement to conduct detailed research investigations, thus driving up total development costs. The regulatory process becomes longer because new clinical studies force manufacturers to delay market entry dates by years. Some manufacturers experience problems in accessing enough historical clinical data that they need for their claims.

Table 3: Impact of Increased Clinical Evidence Requirements

Issue	Description	Impact on Manufacturers
Higher cost of compliance	Increased need for clinical trials and regulatory documentation.	Strains financial resources, especially for SMEs.
Extended development cycle	Additional clinical investigations extend time-to-market.	Delays product launch, affecting competitiveness.
Stricter post-market follow-up	More robust post-market clinical follow-up is required.	Requires ongoing investment in monitoring and reporting.

Notified bodies adopt inconsistent approaches when reviewing medical device specifications, creating challenges under the MDR due to differing interpretations of clinical evaluation requirements. This results in three key issues: Manufacturers struggle to navigate varying document requirements enforced by different bodies across Europe. When submitting initial applications, manufacturers face additional assessments and increased costs due to differing interpretation methods, leading to delays. Furthermore, regulatory planning is disrupted as companies must engage with multiple notified bodies for necessary approvals, increasing complexity.

Table 4: Challenges with Notified Body Variability

Challenge	Description	Impact on Manufacturers
Differing interpretations	Notified bodies enforce clinical evaluation criteria inconsistently.	Creates confusion in regulatory compliance.
Increased documentation requirements	Some notified bodies demand more extensive clinical data than others.	Forces manufacturers to conduct additional studies.
Repeated approval delays	Unclear regulatory expectations lead to multiple review cycles.	Extends time-to-market, increasing costs.

A significant issue has emerged due to the shortage of suitable notified bodies operating under MDR regulations. Many previously active bodies failed to achieve re-designation, limiting options for medical device reviews. As a result, regulatory approval processes have become increasingly prolonged, with fewer notified bodies available to handle the high demand. This limited capacity causes delays in manufacturing, as companies struggle to secure timely approval. Furthermore, the scarcity of notified bodies has led to increased service fees, raising the overall costs for manufacturers seeking certification.

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

Table 5: Impact of Limited Notified Bodies

Problem	Description	Consequence for Manufacturers
Fewer notified bodies	Not all notified bodies have been re-designated under MDR.	Reduces available regulatory partners.
Increased review backlogs	The large volume of applications exceeds the processing capacity.	Lengthens approval timelines.
Rising certification costs	Higher fees are charged due to increased demand.	Financial strain on manufacturers.

Meeting the MDR's requirements incurs significant financial costs, as it involves clinical performance studies, expert consultations, and continuous market monitoring. This economic burden particularly affects small to medium-sized enterprises (SMEs), which face considerable challenges in implementing costly regulatory processes due to limited financial resources. High compliance costs not only reduce available funding for innovation and research but also lead some manufacturers to withdraw certain products from the European market, given the substantial financial strain.

Table 6: Economic Impact of MDR Compliance

Expense	Description	Effect on Manufacturers
Increased clinical trial costs	More rigorous evidence requirements drive up study expenses.	Limits product development for SMEs.
Regulatory consulting fees	Companies require expert assistance to navigate MDR.	Raises overall compliance costs.
Post-market surveillance costs	Continuous monitoring and reporting obligations.	Requires additional personnel and investment.

The stringent medical approval standards lead to extended time-to-market for medical device companies, delaying product introduction and reducing their competitive advantage. Lengthy approval processes for new technologies are exacerbated by regulatory evaluations, further delaying product releases. Consequently, certification delays not only hinder companies but also result in patients waiting longer to access new medical options.

Table 7: Consequences of Extended Approval Timelines

Factor	Description	Industry Impact
Slower product approvals	Longer regulatory review periods under MDR.	Delays commercialization of new devices.
Reduced innovation cycles	Increased compliance burden stifles product development.	Slows down industry growth.
Limited patient access	Regulatory delays postpone the availability of new treatments.	Affects healthcare outcomes.

Manufacturers must implement robust post-market surveillance (PMS) and post-market clinical follow-up (PMCF) systems to comply with the MDR. This includes ongoing surveillance, event reporting, and clinical evaluation updates. Challenges arise as manufacturers require dedicated staff for compliance, and failure to meet MDR standards results in legal and financial penalties. Additionally, data collection becomes more complex, necessitating advanced infrastructure systems.

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

Table 8: Challenges of Post-Market Surveillance

Issue	Description	Impact on Manufacturers
Increased reporting obligations	More frequent data submissions are required.	Adds administrative burden.
Need for continuous monitoring.	Devices require long-term safety assessments.	Ongoing resource allocation is needed.
Risk of non-compliance penalties	Failure to meet PMS requirements leads to regulatory action.	Potential product recalls and fines.

The discussion demonstrates that while the MDR's strengthened clinical evaluation requirements improve patient safety and device effectiveness, they also pose significant challenges for manufacturers. The increased burden of clinical evidence, inconsistencies among notified bodies, limited regulatory capacity, financial strain, prolonged approval timelines, and extensive post-market surveillance requirements create substantial obstacles to compliance.
To mitigate these challenges, manufacturers must adopt proactive strategies, such as engaging early with notified bodies, leveraging real-world clinical data, investing in regulatory expertise, and optimizing post-market surveillance systems. These approaches will be crucial for ensuring regulatory compliance while maintaining competitiveness in the evolving European medical device market.

CONCLUSION

EU MDR European Union Medical Device Regulations have substantially changed medical device manufacturer requirements for completing clinical evaluations. The designed purpose of these regulations included enhanced safety for patients along with both better product effectiveness and stronger post-market oversight; however they brought many burdens for manufacturers. The European market has become challenging for businesses because of stringent clinical evidence demands and varying interpretations by notified bodies and scarce regulatory review organizations which place heavy costs on companies.
The difficulty of obtaining enough clinical data has become a critical challenge because it leads to longer approvals and more expensive compliance steps. The limited resources of small and medium-sized enterprises impede their ability to fulfill the requirements while striving for EU market access. Compliance difficulties increase because notified bodies adopt different interpretation methods that result in both uncertainty and long delays. The restricted pool of designated notified bodies leads to a bottleneck effect that reduces medical device approval speeds, thus delaying entry opportunities for new product innovations.
The MDR implementation difficulties require manufacturers to take deliberate operational steps to succeed with their compliance efforts. The regulatory burden can be reduced by what manufacturers do to interact with notified bodies from the start of their operations and develop strategies that use proof from real-life situations and make the best use of regulations and build up expertise in following rules. Companies involved in compliance work together with regulatory authorities to develop better regulations that will produce predictable and streamlined compliance processes.
Manufacturers encounter substantial obstacles from stronger EU MDR clinical assessment requirements, but this challenge enables them to strengthen their regulatory system and product safety measures while developing better compliance frameworks. The medical device industry depends on successful adaptation to new requirements because market competitiveness requires it, along with ongoing innovation in the field.

REFERENCES

1. Aronson, N. (2017) Patient Access to High-Risk Devices for Unmet Medical Needs. The Pew Charitable Trusts. Available at: https://www.pewtrusts.org (Accessed: 1 March 2025).
2. Bock, A., Sträter, L. and von Cossel, J. (2021) 'Challenges in Clinical Evaluation of Medical Devices under MDR', Regulatory Affairs Journal, 36(4), pp. 210–225.

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

3. Borfitz, D. (2019) 'Clinical Evaluation Reports: A Critical Step in Medical Device Approval', Medical Device Journal, 45(2), pp. 55–68.
4. Charnley, G. (2022) 'Regulatory Considerations for Legacy Devices under MDR', Journal of Medical Regulation, 15(3), pp. 178–190.
5. Cohen, J. and Creinin, M.D. (2020) 'Medical Device Regulations and Their Impact on Clinical Evaluations', Journal of Clinical Studies, 22(1), pp. 89–101.
6. European Commission (2020) Guidance on Clinical Evaluation (MDR 2017/745). Available at: https://ec.europa.eu (Accessed: 1 March 2025).
7. FDA (2021) Clinical Evidence for Medical Devices: A Guide for Manufacturers. U.S. Food and Drug Administration. Available at: https://www.fda.gov (Accessed: 1 March 2025).
8. Fischer, M. and Tait, J. (2019) 'Notified Bodies and the Implementation of MDR', Medical Device Regulatory Affairs, 34(6), pp. 315–329.
9. Gagliardi, D., Murphy, M. and Singh, R. (2022) 'Post-Market Surveillance for High-Risk Medical Devices', Health Policy Journal, 28(2), pp. 112–126.
10. Greenhalgh, T. and Papoutsi, C. (2018) 'Real-World Evidence and Clinical Evaluation of Medical Devices', British Medical Journal, 362, k2853.
11. Konoplev, S., Rassidakis, G.Z., Estey, E., Kantarjian, H., Liakou, C.I., Huang, X., et al. (2007) 'Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype', Cancer: Interdisciplinary International Journal of the American Cancer Society, 188.
12. Kouvaraki, M.A., Liakou, C., Paraschi, A., Dimas, K., Patsouris, E., et al. (2012) 'Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas', Surgery, 150(6), pp. 1258-1265.
13. Liakou, C.I., Kamat, A., Tang, D.N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., et al. (2008) 'CTLA-4 blockade increases IFNγ-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients', Proceedings of the National Academy of Sciences, 105(39), pp. 14987-14992.
14. Liakou, C.I., Narayanan, S., Tang, D.N., Logothetis, C.J., Sharma, P. (2007) 'Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer', Cancer Immunity, 7(1), p. 10.
15. Kearney, Breda, and Olivia McDermott. "Challenges faced by manufacturers with clinical evaluation under the new European Medical Device Regulations." *Cogent Engineering* 10.2 (2023): 2261236. https://doi.org/10.1080/23311916.2023.2261236
16. Kearney, Breda, and Olivia McDermott. "The challenges for manufacturers of the increased clinical evaluation in the European medical device regulations: a quantitative study." *Therapeutic Innovation & Regulatory Science* 57.4 (2023): 783-796.
17. European Commission. (2021). Regulation (EU) 2017/745 on Medical Devices (MDR). Official Journal of the European Union. Retrieved from https://eur-lex.europa.eu
18. European Commission. (2020). Guidance on Clinical Evaluation (MDR) – MEDDEV 2.7/1 Rev. 4. Retrieved from https://ec.europa.eu
19. International Medical Device Regulators Forum (IMDRF). (2021). Clinical Evaluation of Medical Devices: Key Definitions and Concepts. Retrieved from https://www.imdrf.org
20. European Association of Notified Bodies. (2022). Challenges of EU MDR Implementation for Medical Device Manufacturers. Journal of Medical Device Regulations, 34(2), 155–170.
21. Müller, R., & Schindler, T. (2023). Impact of EU MDR on Small and Medium-Sized Enterprises in the Medical Device Industry. Regulatory Affairs Journal, 45(1), 78–91.
22. Smith, P., & Keller, B. (2022). Post-Market Surveillance Systems under EU MDR: Compliance and Operational Challenges. European Journal of Medical Device Compliance, 29(3), 203–218.
23. Notified Bodies Coordination Group (NBCG). (2023). Harmonization of Clinical Evaluation Criteria under EU MDR. NBCG White Paper.
24. Johnson, L., & Park, C. (2022). The Role of Clinical Investigations in Demonstrating Medical Device Safety and Efficacy under MDR. Journal of Clinical Research Compliance, 17(4), 112–125.

iJETRM
International Journal of Engineering Technology Research & Management
Published By:
https://www.ijetrm.com/

25. World Health Organization (WHO). (2021). Global Regulatory Frameworks for Medical Devices: A Comparative Study. Geneva: WHO Press.
26. European Medical Device Coordination Group (MDCG). (2023). Guidelines on Post-Market Clinical Follow-Up under MDR. Retrieved from https://ec.europa.eu